Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma

NCT04995120 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Laryngeal Cancer
Hypopharynx Cancer
Laryngeal Neoplasms

Interventions

DRUG: chemotherapy TP regimen combined with Toripalimab

Sponsor

Fudan University